Ensysce Biosciences, Inc. (ENSC)

NASDAQ: ENSC · IEX Real-Time Price · USD
0.745
-0.005 (-0.67%)
At close: Apr 12, 2024, 4:00 PM
0.750
+0.005 (0.64%)
After-hours: Apr 12, 2024, 7:51 PM EDT
-0.67%
Market Cap 2.34M
Revenue (ttm) n/a
Net Income (ttm) -10.63M
Shares Out 3.15M
EPS (ttm) -4.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,418
Open 0.750
Previous Close 0.750
Day's Range 0.740 - 0.759
52-Week Range 0.721 - 7.200
Beta 0.76
Analysts Strong Buy
Price Target 7.00 (+839.6%)
Earnings Date May 13, 2024

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ENSC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ENSC stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(839.60% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

SAN DIEGO, CA / ACCESSWIRE / April 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pa...

4 days ago - Accesswire

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans SAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / ...

4 weeks ago - Accesswire

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

SAN DIEGO, CA / ACCESSWIRE / February 27, 2024 / Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety...

6 weeks ago - Accesswire

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

~ PF614-MPAR program receives FDA guidance ~ SAN DIEGO, CA / ACCESSWIRE / February 21, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company applying tr...

7 weeks ago - Accesswire

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

Publication Details Positive Results of Clinical Study PF614-102 SAN DIEGO, CA / ACCESSWIRE / February 15, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)(OTC PINK:ENSCW) ("Ensysce" or "Company"), a cl...

2 months ago - Accesswire

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription dru...

2 months ago - Accesswire

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

~ PF614-MPAR recognized as potential medical breakthrough ~ SAN DIEGO, CA / ACCESSWIRE / February 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company a...

2 months ago - Accesswire

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

~ PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 ~ SAN DIEGO, CA / ACCESSWIRE / January 31, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stag...

2 months ago - Accesswire

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

SAN DIEGO, CA / ACCESSWIRE / January 25, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve pres...

2 months ago - Accesswire

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

~ FDA acknowledges significant potential impact of MPAR's oral overdose protection ~ SAN DIEGO, CA / ACCESSWIRE / January 23, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC...

2 months ago - Accesswire

Ensysce Biosciences Issues 2024 Shareholder Letter

SAN DIEGO, CA / ACCESSWIRE / January 8, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription ...

3 months ago - Accesswire

Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

SAN DIEGO, CA / ACCESSWIRE / December 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced that the Company's Special Meeting of Stockholders (the "Special ...

4 months ago - Accesswire

Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic

Results Reinforce Efficacy of PF614 as a Next Generation Analgesic with Significant Pain Intensity Reduction PF614 Clinical Data Primes FDA Evaluation and Design of Phase 3 Studies in 2024 SAN DIEGO, ...

4 months ago - Accesswire

Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast

PHOENIX, AZ / ACCESSWIRE / December 11, 2023 / The Stock Day Podcast welcomed Ensysce Biosciences (NASDAQ:ENSC) ("the Company"), a clinical-stage company using its proprietary technology platforms to ...

4 months ago - Accesswire

Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing

Additional Funding from Investors Validates Company's Mission SAN DIEGO, CA / ACCESSWIRE / November 29, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage co...

4 months ago - Accesswire

Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States

Collaboration Aims to Accelerate Development of BupiZenge™, a Novel Pain Treatment for Oral Mucositis Associated with Cancer Treatment SAN DIEGO, CA and STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2...

4 months ago - Accesswire

Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study

~ Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 ~ ~ Trial Results Expected in December 2023 ~ SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ...

5 months ago - Accesswire

Ensysce Biosciences Reports Third Quarter 2023 Financial Results

PF614-201 Clinical Study Results Expected by End of Year SAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company ...

5 months ago - Accesswire

Ensysce Biosciences Secures $1.7 Million Convertible Note Financing

Additional Funding from Investor Cohort Validates Company's Mission SAN DIEGO, CA / ACCESSWIRE / October 24, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW)...

6 months ago - Accesswire

Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360

Poster Presentation to Showcase the Optimization Process of Ensysce's PF614-MPAR Formulation SAN DIEGO, CA / ACCESSWIRE / October 18, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Comp...

6 months ago - Accesswire

Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium

~ A showcase of PF614 and PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / October 13, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformativ...

6 months ago - Accesswire

Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit

~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~ SAN DIEGO, CA / ACCESSWIRE / October 11, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage co...

6 months ago - Accesswire

Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023

~ Geoff Birkett, CCO of Ensysce, to Chair Meeting, Deliver Opening Remarks and Present a Case Study on Drug Launch Process ~ SAN DIEGO, CA / ACCESSWIRE / October 3, 2023 / Ensysce Biosciences, Inc. (N...

6 months ago - Accesswire

Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study

~ Study Initiation Brings PF614 One Necessary Step Closer to Phase 3 ~ ~ Trial Results Expected Before Year End 2023 ~ SAN DIEGO, CA / ACCESSWIRE / September 26, 2023 / Ensysce Biosciences, Inc. ("Ens...

7 months ago - Accesswire

Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023

~ Moderated Session to Review Latest Data as Recently Presented ~ SAN DIEGO, CA / ACCESSWIRE / September 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-sta...

7 months ago - Accesswire